Immunotherapy partners after progression: Right place, right time?
Mené sur 35 patients atteints d'un cancer un poumon non à petites cellules de stade avancé ayant progressé après un traitement par anti-PD-1/PD-L1, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du pembrolizumab en combinaison avec une chimiothérapie
This editorial aims to place the trial of pembrolizumab plus next line chemotherapy by Salous et al. in the context of other clinical trials evaluating different strategies to extend the benefit of immunotherapy after disease progression. Included in this article are the INSIGNA trial, off-protocol treatment beyond progression, local ablative therapy with radiation, the recently published Lung-MAP S1800A study, and a summary of other immunotherapy-based combinations currently under investigation.
Cancer , éditorial, 2021